Good Read28 Aug 2018 18:58
a further commercial arrangement is UNDER NEGOTIATION with parties to run the final required trial, with possibilities still available for inward investment in exchange for regional commercialisation rights, equity positions in ValiSeek, or options for future commercial rights.
This final trial carries the weight of all our hopes for the future of VAL401, with investors recognising the risks involved in any life science investment: that clinical trials are complex to operate, can take longer than anticipated to recruit patients, and are genuine experimental science, so they can provide results other than those expected.
______________
So how long before we need to debate the wording of "under negotiation" lol. Good to actually hear an update... will the market react?